CD200R1 and myeloid sarcoma: Little is known of the changes occurring in CD200 and CD200R1 expression, or in the mechanisms that regulate this expression under physiological and pathological conditions in the CNS, but it has been suggested that the CD200-CD200R1 system could be a candidate therapeutic target in MS (Koning et al., 2009b).